$0.95+11.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
The quarter ending December 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2023 | 3 months toDec 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | -$3.8M | -$7.1M | +46.65% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Perspective Therapeutics, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced systemic treatments for cancers. The Company has proprietary technology that utilizes the alpha-generating isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity. The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors). The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224 Ra/ 212 Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Perspective Therapeutics, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.